[ET Net News Agency, 1 November 2017] Credit Suisse assumed coverage on 3SBio Inc.
(01530) with a "neutral" rating, and a target price of HK$15.4 (up from HK$8.6).
The research house sees the domestic industry leader to benefit the most from the
emerging China healthcare market, superior to MNCs and small domestic players. 3SBio, as a
leader in biologic drugs in China, has plenty of R&D and commercialisation experiences.
Besides, Credit Suisse believes it would be able to further strengthen its pipeline by
M&A and inhouse R&D in the future. Despite the strong fundamentals, the company is now
trading at 29x FY2018 P/E after stock price surged by 74% in the last 12 months; Credit
Suisse believes the upside is limited with such a high valuation. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01530 3SBIO
Nominal 
5.560 -0.100 (-1.767%) Others
01/11/2017 16:50
[I-bank focus]CS restarts 3SBio Inc. (01530) at HK$15.4
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |